scholarly journals Professionals' knowledge, attitude and referral behaviour of preimplantation genetic diagnosis for hereditary breast and ovarian cancer

2018 ◽  
Vol 36 (2) ◽  
pp. 137-144 ◽  
Author(s):  
J.J.G. Gietel-Habets ◽  
C.E.M. de Die-Smulders ◽  
V.C.G. Tjan-Heijnen ◽  
I.A.P. Derks-Smeets ◽  
R. van Golde ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Breast And Ovarian Cancer ◽  
Referral Behaviour

scholarly journals Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer

2014 ◽  
Vol 29 (5) ◽  
pp. 1103-1112 ◽  
Author(s):  
I. A. P. Derks-Smeets ◽  
J. J. G. Gietel-Habets ◽  
A. Tibben ◽  
V. C. G. Tjan-Heijnen ◽  
M. Meijer-Hoogeveen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Decision Making ◽  
Prenatal Diagnosis ◽  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Breast And Ovarian Cancer

scholarly journals Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer

2009 ◽  
Vol 11 (10) ◽  
pp. 757-765 ◽  
Author(s):  
Susan T Vadaparampil ◽  
Gwendolyn P Quinn ◽  
Caprice Knapp ◽  
Teri L Malo ◽  
Susan Friedman
Keyword(s):  
Ovarian Cancer ◽  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Breast And Ovarian Cancer ◽  
Factors Associated

scholarly journals SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)

2019 ◽  
Vol 22 (2) ◽  
pp. 193-200 ◽  
Author(s):  
S. González-Santiago ◽  
◽  
T. Ramón y Cajal ◽  
E. Aguirre ◽  
J. E. Alés-Martínez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Genetic Diagnosis ◽  
Treatment Strategies ◽  
Parp Inhibitors ◽  
Breast And Ovarian Cancer ◽  
Brca Mutations ◽  
Clinical Criteria ◽  
Therapeutic Implications ◽  
New Genes

AbstractMutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. Multigene cancer panels provide new challenges related to increased frequency of variants of uncertain significance, new gene-specific cancer risk assessments, and clinical recommendations for carriers of mutations of new genes. Although clinical criteria for genetic testing continue to be largely based on personal and family history with around a 10% detection rate, broader criteria are being applied with a lower threshold for detecting mutations when there are therapeutic implications for patients with breast or ovarian cancer. In this regard, new models of genetic counselling and testing are being implemented following the registration of PARP inhibitors for individuals who display BRCA mutations. Massive sequencing techniques in tumor tissue is also driving a paradigm shift in genetic testing and potential identification of germline mutations. In this paper, we review the current clinical criteria for genetic testing, as well as surveillance recommendations in healthy carriers, risk reduction surgical options, and new treatment strategies in breast cancer gene-mutated carriers.

scholarly journals High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer

2010 ◽  
Vol 25 (10) ◽  
pp. 2543-2550 ◽  
Author(s):  
Gwendolyn P. Quinn ◽  
Susan T. Vadaparampil ◽  
Cheryl A. Miree ◽  
Ji-Hyun Lee ◽  
Xiuhua Zhao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Genetic Diagnosis ◽  
Breast And Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document